Revumenib 25 mg, 110 mg, 160 mg Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 25 mg, 110 mg, 160 mg

Reference Brands: Revuforj (USA)

Category: Oncology Cancer Care

Revumenib is a Oncology Cancer Care product available as Tablets in strengths 25 mg, 110 mg, 160 mg. It corresponds to the reference brand Revuforj (USA). Verified GMP manufacturers and suppliers on PharmaTradz offer it in bulk for import worldwide, with regulatory documentation and dossier support available on request.

Product Description:

Revumenib is an oral targeted anticancer medication used for the treatment of acute leukemias with lysine methyltransferase 2A (KMT2A) gene rearrangements and is marketed under the brand name Revuforj. It is specifically indicated for patients whose cancers harbor KMT2A translocations, which are known to drive aggressive leukemia progression.

Revumenib works as a menin inhibitor, disrupting the interaction between the menin protein and KMT2A (also called MLL). This interaction is critical for the survival and proliferation of leukemia cells in patients with KMT2A-rearranged acute leukemia. By blocking this pathway, revumenib helps to slow or halt cancer cell growth, providing a precision oncology approach for patients with genetically defined leukemias.

Administered orally as a film-coated tablet, revumenib offers a convenient dosing option while targeting the molecular drivers of the disease. It is generally used under medical supervision, with prior genetic testing to confirm the presence of KMT2A gene rearrangements. Revumenib represents an important therapeutic option for patients with difficult-to-treat, relapsed, or refractory acute leukemias driven by specific genetic abnormalities.